In 2023, the sales of obstructive airway diseases medicine in Canada stood at approximately 2.09 billion Canadian dollars. The forecasted trend from 2024 to 2028 indicates a steady growth in sales: from 2.14 billion CAD in 2024 to 2.39 billion CAD in 2028. This represents a year-on-year increase of around 2.8% to 3% and a compound annual growth rate (CAGR) of approximately 2.8% over the five-year period. The consistent upward trajectory suggests a robust market outlook, driven by factors such as rising prevalence of obstructive airway diseases and advancements in medication.
Future trends to watch include potential impacts of healthcare policy changes, emerging alternative therapies, and technological advancements in drug delivery systems. Additionally, monitoring shifts in consumer preferences towards personalized medicine and sustainability considerations might also influence market dynamics.
